|
1
|
Brown KM, Xue A, Mittal A, Samra JS, Smith
R and Hugh TJ: Patient-derived xenograft models of colorectal
cancer in pre-clinical research: A systematic review. Oncotarget.
7:66212–66225. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Veettil SK, Lim KG, Chaiyakunapruk N,
Ching SM and Abu Hassan MR: Colorectal cancer in Malaysia: Its
burden and implications for a multiethnic country. Asian J Surg.
40:481–489. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Saudi Cancer Registry: Cancer Incidence
Report Saudi Arabia 2015. Ministry of Health; Kingdom of Saudi
Arabia: 2018
|
|
4
|
Szakács G, Paterson JK, Ludwig JA,
Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in
cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Katayama K, Noguchi K and Sugimoto Y:
Regulations of P-glycoprotein/ABCB1/MDR1 in human cancer cells. New
J Sci. 10:2014.
|
|
6
|
Dean M, Rzhetsky A and Allikmets R: The
human ATP-binding cassette (ABC) transporter superfamily. Genome
Res. 11:1156–1166. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mencalha AL, Rodrigues EF, Abdelhay E and
Fernandez TS: Accurate monitoring of promoter gene methylation with
high-resolution melting polymerase chain reaction using the ABCB1
gene as a model. Genet Mol Res. 12:714–722. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Panczyk M, Balcerczak E, Piaskowski S,
Jamroziak K, Pasz-Walczak G and Mirowski M: ABCB1 gene
polymorphisms and haplotype analysis in colorectal cancer. Int J
Colorectal Dis. 24:895–905. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Campa D, Sainz J, Pardini B, Vodickova L,
Naccarati A, Rudolph A, Novotny J, Försti A, Buch S, von Schönfels
W, et al: A comprehensive investigation on common polymorphisms in
the MDR1/ABCB1 transporter gene and susceptibility to colorectal
cancer. PLoS One. 7:e327842012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
He T, Mo A, Zhang K and Liu L: ABCB1/MDR1
gene polymorphism and colorectal cancer risk: A meta-analysis of
case-control studies. Colorectal Dis. 15:12–18. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang F, Huang Z, Zheng K, Zhao H and Hu W:
Two SNPs of ATP-binding cassette B1 gene on the risk and prognosis
of colorectal cancer. Int J Clin Exp Pathol. 8:3083–3089.
2015.PubMed/NCBI
|
|
12
|
Petrova DT, Nedeva P, Maslyankov S, Toshev
S, Yaramov N, Atanasova S, Toncheva D, Oellerich M and von Ahsen N:
No association between MDR1 (ABCB1) 2677G>T and 3435C>T
polymorphism and sporadic colorectal cancer among Bulgarian
patients. J Cancer Res Clin Oncol. 134:317–322. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jamroziak K, Balcerczak E, Calka K,
Piaskowski S, Urbanska-Rys H, Salagacka A, Mirowski M and Robak T:
Polymorphisms and haplotypes in the multidrug resistance 1 gene
(MDR1/ABCB1) and risk of multiple myeloma. Leuk Res. 33:332–335.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Maleki M, Sayyah M, Kamgarpour F,
Karimipoor M, Arab A, Rajabi A, Gharagozli K, Shamshiri AR and
Shahsavand Ananloo E: Association between ABCB1-T1236C polymorphism
and drug-resistant epilepsy in Iranian female patients. Iran Biomed
J. 14:89–96. 2010.PubMed/NCBI
|
|
15
|
Wu H, Kang H, Liu Y, Xiao Q, Zhang Y, Sun
M, Liu D, Wang Z, Zhao H, Yao W, et al: Association of ABCB1
genetic polymorphisms with susceptibility to colorectal cancer and
therapeutic prognosis. Pharmacogenomics. 14:897–911. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Patt YZ, Lee FC, Liebmann JE, Diamandidis
D, Eckhardt SG, Javle M, Justice GR, Keiser W, Salvatore JR, Bexon
A and Lin E: Capecitabine plus 3-weekly irinotecan (XELIRI regimen)
as first-line chemotherapy for metastatic colorectal cancer: Phase
II trial results. Am J Clin Oncol. 30:350–357. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Alcindor T and Beauger N: Oxaliplatin: A
review in the era of molecularly targeted therapy. Curr Oncol.
18:18–25. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Luo HY, Wang ZQ, Wang FH, Qiu MZ, Teng KY,
Ruan DY, He YJ, Li YH and Xu RH: Phase 2 study of capecitabine and
irinotecan combination chemotherapy (modified XELIRI regimen) in
patients with advanced gastric cancer. Am J Clin Oncol. 34:555–560.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Puppa G, Sonzogni A, Colombari R and
Pelosi G: TNM staging system of colorectal carcinoma: A critical
appraisal of challenging issues. Arch Pathol Lab Med. 134:837–852.
2010.PubMed/NCBI
|
|
20
|
Hall C, Clarke L, Pal A, Buchwald P,
Eglinton T, Wakeman C and Frizelle F: A review of the role of
carcinoembryonic antigen in clinical practice. Ann Coloproctol.
35:294–305. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tanabe M, Ieiri I, Nagata N, Inoue K, Ito
S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, et al:
Expression of P-glycoprotein in human placenta: Relation to genetic
polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol
Exp Ther. 297:1137–1143. 2001.PubMed/NCBI
|
|
22
|
Chapco W: An exact test of the
Hardy-Weinberg law. Biometrics. 32:183–189. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tam V, Patel N, Turcotte M, Bossé Y, Paré
G and Meyre D: Benefits and limitations of genome-wide association
studies. Nat Rev Genet. 20:467–484. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Özhan G, Kara M, Sari FM, Yanar HT, Ercan
G and Alpertunga B: Associations between the functional
polymorphisms in the ABCB1 transporter gene and colorectal cancer
risk: A case-control study in Turkish population. Toxicol Mech
Methods. 23:235–239. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
De Iudicibus S, De Pellegrin A, Stocco G,
Bartoli F, Bussani R and Decorti G: ABCB1 gene polymorphisms and
expression of P-glycoprotein and long-term prognosis in colorectal
cancer. Anticancer Res. 28:3921–3928. 2008.PubMed/NCBI
|
|
26
|
Kim HJ, Um JY and Kim YK: Association of a
multidrug resistance 1 gene polymorphism and colorectal cancer in
the Korean population. Orient Pharm Exp Med. 13:225–230. 2013.
View Article : Google Scholar
|
|
27
|
Kim CG, Ahn JB, Jung M, Beom SH, Heo SJ,
Kim JH, Kim YJ, Kim NK, Min BS, Koom WS, et al: Preoperative serum
carcinoembryonic antigen level as a prognostic factor for
recurrence and survival after curative resection followed by
adjuvant chemotherapy in stage III colon cancer. Ann Surg Oncol.
24:227–235. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Thirunavukarasu P, Talati C, Munjal S,
Attwood K, Edge SB and Francescutti V: Effect of incorporation of
pretreatment serum carcinoembryonic antigen levels into AJCC
staging for colon cancer on 5-year survival. JAMA Surg.
150:747–755. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim YO, Kim MK, Woo YJ, Lee MC, Kim JH,
Park KW, Kim EY, Roh YI and Kim CJ: Single nucleotide polymorphisms
in the multidrug resistance 1 gene in Korean epileptics. Seizure.
15:67–72. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Butila AT, Sin A, Szabo ER, Micheu C,
Moldovan VG, Voidazan S and Bănescu C: ABCB1 gene polymorphisms is
not associated with drug-resistant epilepsy in Romanian children.
Rev Romana Med Lab. 23:469–482. 2015.
|
|
31
|
Alsaif AA, Hasan TN, Shafi G, Syed NA,
Alsaif MA, Al-Assaf AH and Alshatwi AA: Association of multiple
drug resistance-1 gene polymorphism with multiple drug resistance
in breast cancer patients from an ethnic Saudi Arabian population.
Cancer Epidemiol. 37:762–766. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou Z, Chen Q, Zuo D, Wang H, Hua Y and
Cai Z: ABCB1 (rs1128503) polymorphism and response to chemotherapy
in patients with malignant tumors-evidences from a meta-analysis.
Int J Clin Exp Med. 8:265–272. 2015.PubMed/NCBI
|
